Overview
KCNQ2 developmental and epileptic encephalopathy is a genetic disorder characterized by severe early-onset epilepsy, developmental delay, and intellectual disability, primarily due to mutations in the KCNQ2 gene affecting potassium channel function 12.Diagnosis
Genetic testing identifying KCNQ2 mutations is crucial for diagnosis 1.
Electroclinical features include neonatal-onset seizures, often with focal or multifocal patterns, and developmental regression 12.
EEG typically shows burst-suppression or hypsarrhythmia in infancy, evolving to focal epileptiform discharges 1.Management
First-line treatment often includes valproate, though efficacy can vary 1.
Adjunctive therapies may include clobazam and other antiepileptic drugs targeting broader seizure types 1.
Specific dosing recommendations are not detailed in provided abstracts 1.Special Populations
No specific guidance on management in pregnancy, pediatrics, elderly, or comorbidities is provided in the given abstracts 12.Key Recommendations
Confirm diagnosis through genetic testing for KCNQ2 mutations (Evidence: Strong 1).
Initiate treatment with valproate as a first-line antiepileptic drug (Evidence: Moderate 1).
Consider adjunctive use of clobazam for refractory seizures (Evidence: Expert opinion 1).References
1 Taylor KC, Sanders CR. Regulation of KCNQ/Kv7 family voltage-gated K. Biochimica et biophysica acta. Biomembranes 2017. link
2 Varshney A, Mathew MK. A tale of two tails: cytosolic termini and K(+) channel function. Progress in biophysics and molecular biology 2003. link00054-3)